Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Fosamprenavir in HIV-1 Infected Subjects
NCT00094523Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Dec 2004
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of fosamprenavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of subjects with HIV-1 RNA less than 400 copies/mL at 24 weeks. Started Dec 2004; status: completed.
02
Drugs
fosamprenavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00094523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094523.